These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36863962)

  • 1. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
    Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P
    Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
    Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
    Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
    Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.
    Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA
    Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis.
    Chen B; Li J; Huang Y; Tang B; Jiang J; Chen Z; Li J; Wang P; Cao D; Liu L; Wei Q
    Int J Surg; 2023 Apr; 109(4):982-994. PubMed ID: 36974696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
    Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
    Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.
    Hara T; Furukawa J; Shiraishi Y; Okamura Y; Bando Y; Terakawa T; Harada K; Nakano Y; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):746-752. PubMed ID: 37130778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN).
    Gunenc D; Issa W; Gerald T; Zhou Q; Zhang S; Ibezue IC; Bhanvadia R; Tachibana I; Brugarolas J; Hammers H; Qin Q; Kapur P; Woldu S; Gaston K; Lotan Y; Cadeddu J; Wang AZ; Margulis V; Zhang T
    Clin Genitourin Cancer; 2024 Oct; 22(5):102177. PubMed ID: 39218752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
    Méjean A; Ravaud A; Thezenas S; Chevreau C; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Oudard S; Laguerre B; Gross-Goupil M; Bernhard JC; Colas S; Albiges L; Lebret T; Treluyer JM; Timsit MO; Escudier B
    Eur Urol; 2021 Oct; 80(4):417-424. PubMed ID: 34187771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
    de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
    Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
    Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.
    Teishima J; Goto K; Sekino Y; Mita K; Hayashi T; Hasegawa Y; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Kobayashi K; Asano K; Hinata N
    Int Urol Nephrol; 2022 Jun; 54(6):1225-1232. PubMed ID: 35314918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
    Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial.
    Park JS; Kim J; Jeon J; Lee J; Jang WS; Lee SH; Han WK; Choi YD; Koo KC; Cho KS; Chung BH; Ham WS
    Trials; 2024 Jul; 25(1):447. PubMed ID: 38961439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.